Thank you International Continence Society (ICS) for having us this morning during #ICS2024 annual conference to present our last results on EG110A for the treatment of Neurogenic Detrusor Overactivity. Congrats to Julien Ratelade, PhD for his presentation. #incontinence #bladderhealth
À propos
At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care. Our HQ and labs are in Paris, France, where we were founded in 2019. We have raised over USD 21 million, including from our Series A in 2021.
- Secteur
- Recherche en biotechnologie
- Taille de l’entreprise
- 11-50 employés
- Siège social
- Paris, Île-de-France
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2019
- Domaines
- Gene therapy, peripheral nervous system disorders, neurogenic bladder, HSV-1 vector platform, urinary bladder dysfunction, Herpes type 1 gene therapy platform et treatment of nervous system disorders
Lieux
-
Principal
Obtenir l’itinéraire
29, Rue du Faubourg Saint-Jacques
75014 Paris, Île-de-France, FR
Employés chez EG 427
-
Dominique Batéjat
-
Philippe Chambon MD, PhD
Chairman, Ceo and founder EG427: entering clinical stage in precision genetherapy for neurology; Vice Chairman and founder Atias Pharmaceutical
-
Don Haut, PhD (he/him)
Biotech Executive and Board Member
-
François Giuliano
Co-founder chez EG427
Nouvelles
-
Don’t miss Julien Ratelade, presenting the award-winning research TODAY at 09:30 CET at #ICS2024 in Madrid! #bladderhealth #incontinence #ICSmeeting #urology International Continence Society (ICS)
We are very proud that our abstract on EG110A at the #ICS2024 meeting of the International Continence Society (ICS) has been awarded a “Best in Category Prize: Research Methods / Techniques”! Our heartiest congratulations to Julien Ratelade, PhD, who is presenting the abstract entitled “EG110A, a novel non-replicative HSV1-derived vector expressing the light chain of botulinum toxin F, shows dose-dependent efficacy in an acute intravesical capsaicin rat model”. The prize is a significant validation by the widely respected ICS of the quality of the preclinical work on EG110A, the first gene therapy for prevalent pathologies in neurology. We are now building on these data with our first-in-human Phase 1b/2a clinical study in Neurogenic Detrusor Overactivity (NDO) patients. Come and see Julien’s presentation of the abstract at ICS 2024 in Madrid on Wednesday, October 23 at 09:30 CET. You can find the abstract here https://lnkd.in/erqpuX4Y and the full ICS 2024 program here https://lnkd.in/eaV6dA9S #genetherapy #biotech #bladderhealth #ICSMeeting #incontinence #urology
-
What an incredible week at EG 427! Today, we're thrilled to present our poster at the European Society of Gene and Cell Therapy Annual Meeting. Join Samuel Salot as he shares insights on “Efficient Retrograde Transport Following Stereotaxic Inoculation in the Striatum of a Non-Replicative HSV-1 Vector”. If you're in Rome, we’d love to meet you! Come by to discuss our latest findings and explore how our work is advancing pinpoint gene therapy in neurology. Stay tuned for more exciting updates throughout the week! #ESGCT2024 #GeneTherapy #Neurology #biotech
-
-
Don't miss today's presentation during Alliance for Regenerative Medicine's Meeting on the Mesa. Don Haut, PhD (he/him) will be presenting the company's progress and upcoming milestones. #genetherapy #CGMesa24
-
-
We’re looking forward to a busy fall, when EG 427 will be attending and presenting at several high-profile industry events. This comes with our first product EG110A now progressing in a first-in-human trial – making EG 427 the second company worldwide to have a product in clinical development using a non-replicative HSV-1 based platform for DNA therapies, and the first in neurology. Come see our presentations and please get in touch if you’d like to learn more about our progress or set up a meeting at one of the following events: · Cell & Gene Meeting on the Mesa, Phoenix, AZ, USA, Oct 7-9 Don Haut, PhD (he/him), Chief Business Officer, will present on Tuesday Oct 8 at 16:45 local time (MST). #CGMesa24 · #ESGCT 2024 (European Society of Gene and Cell Therapy), Rome, Italy, Oct 22-25 Samuel Salot, COO, will present during Poster Session I, Tuesday Oct 22 from 19:30 to 21:00 local time (CET) · International Continence Society (ICS) 2024, Madrid, Spain, Oct 23-25 Julien Ratelade, PhD will make an oral presentation, which has won a best in category prize during Session 3 Neurological, Wednesday Oct 23 at 08:30 local time (CET) Listen to his interview during ICS Live Lounge, Wednesday Oct 23 at 10:05 during the coffee break · 6th Annual Gene Therapy for CNS Summit, Boston, MA, USA, Nov 20-22 Teddy JÉGU, Director of Vectorology, will talk about how non-replicative HSV vectors can be used in the central nervous system to develop new therapeutic approaches. #genetherapy #biotech #investing #technology
-
EG 427 a republié ceci
Want to know more #incontinence statistics from the Urge to Act continence report? You can continue to help raise awareness and support greater continence care with these helpful facts. Together we can create a more patient-centred and holistic approach to continence care. #urologyweek
-
-
Merci à la SATT Paris-Saclay pour cet article qui retrace notre parcours, depuis la recherche à l'UVSQ Université de Versailles Saint-Quentin-en-Yvelines jusqu'à notre entrée en étude clinique.
Zoom start-up : EG 427 lance sa première étude clinique chez l’homme - SATT Paris Saclay
https://satt-paris-saclay.fr
-
It's #UrologyWeek, and we at EG 427 are proud to highlight our ongoing commitment to developing new therapies for patients suffering from urinary incontinence. Urinary incontinence can be particularly challenging for individuals with neurological conditions or an overactive bladder that isn’t properly managed by existing treatments. That’s why we're developing EG110A, our innovative drug candidate designed to provide long-term relief for these patients, avoid the current drugs' side effects and significantly improve their quality of life. Urinary incontinence isn’t just a medical challenge—it’s also a significant economic burden both for patients and healthcare systems. According to the European Association of Urology (EAU) in its "Urge to act" manifesto, the cost in Europe only was estimated at a staggering €69.1 billion in 2023. Currently, EG110A is entering its first clinical trial in patients with neurogenic bladder following spinal cord injury – a key milestone in our journey to help those most in need. We're dedicated to advancing safe and effective treatments that address unmet needs in urology, and we look forward to sharing our progress. Stay tuned! #UrologyWeek2024 #Urology #HealthcareInnovation #BladderHealth #NeurogenicBladder #ClinicalTrials #genetherapy
-
-
Merci Olivier Gosset pour ce coup de projecteur sur les biotechs françaises et sur EG 427 en particulier.
Comme en Belgique, la filière française des sciences de la vie est en plein essor. Depuis le Brexit, elle est même considérée comme la plus importante dans l'Union européenne. Elle est confrontée aux mêmes problèmes de financement que l'écosystème de notre pays, qu'elle lorgne avec intérêt. https://lnkd.in/gXKt4TV7
Pourquoi la filière biotech française lorgne la Belgique
lecho.be
-
Our Chief Business Officer Don Haut, PhD (he/him) will be presenting at the 2024 #BioCenturyGrandRounds of business leaders, investors, and scientists, being held September 9-11 in Nashville, USA. Don will be presenting EG 427, its strategy and future prospects on Tuesday, September 10 10:50 AM Central Time. Please get in touch if you would like to schedule a meeting at the event. More details below. https://lnkd.in/gakuvuEn #biotech #biopharma BioCentury Inc.
-